These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 27813323)

  • 21. Nanocarriers for the treatment of glioblastoma multiforme: Current state-of-the-art.
    Karim R; Palazzo C; Evrard B; Piel G
    J Control Release; 2016 Apr; 227():23-37. PubMed ID: 26892752
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted delivery of miRNA based therapeuticals in the clinical management of Glioblastoma Multiforme.
    Pottoo FH; Javed MN; Rahman JU; Abu-Izneid T; Khan FA
    Semin Cancer Biol; 2021 Feb; 69():391-398. PubMed ID: 32302695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for anti-glioblastoma treatment.
    Kang T; Zhu Q; Jiang D; Feng X; Feng J; Jiang T; Yao J; Jing Y; Song Q; Jiang X; Gao X; Chen J
    Biomaterials; 2016 Sep; 101():60-75. PubMed ID: 27267628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
    Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
    Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration.
    Gao H; Xiong Y; Zhang S; Yang Z; Cao S; Jiang X
    Mol Pharm; 2014 Mar; 11(3):1042-52. PubMed ID: 24521297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells.
    Tivnan A; Heilinger T; Ramsey JM; O'Connor G; Pokorny JL; Sarkaria JN; Stringer BW; Day BW; Boyd AW; Kim EL; Lode HN; Cryan SA; Prehn JH
    Oncotarget; 2017 Mar; 8(10):16605-16620. PubMed ID: 28178667
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Gallego L; Ceña V
    Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo intracellular distribution and anti-glioblastoma effects of docetaxel-loaded nanoparticles functioned with IL-13 peptide.
    Gao H; Zhang S; Yang Z; Cao S; Jiang X; Pang Z
    Int J Pharm; 2014 May; 466(1-2):8-17. PubMed ID: 24607217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The challenges associated with molecular targeted therapies for glioblastoma.
    Jue TR; McDonald KL
    J Neurooncol; 2016 May; 127(3):427-34. PubMed ID: 26900075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
    Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
    Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.
    Westphal M; Maire CL; Lamszus K
    CNS Drugs; 2017 Sep; 31(9):723-735. PubMed ID: 28791656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delivery systems and molecular targets of mechanism-based therapies for GBM.
    Phuphanich S; Brat DJ; Olson JJ
    Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Glioblastoma with the Use of Phytocompounds and Nanoparticles.
    Pistollato F; Bremer-Hoffmann S; Basso G; Cano SS; Elio I; Vergara MM; Giampieri F; Battino M
    Target Oncol; 2016 Feb; 11(1):1-16. PubMed ID: 26275397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthetic nano-LDL with paclitaxel oleate as a targeted drug delivery vehicle for glioblastoma multiforme.
    Nikanjam M; Gibbs AR; Hunt CA; Budinger TF; Forte TM
    J Control Release; 2007 Dec; 124(3):163-71. PubMed ID: 17964677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
    Reardon DA; Wen PY
    Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
    [TBL] [Abstract][Full Text] [Related]  

  • 36. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma.
    Whittle JR; Lickliter JD; Gan HK; Scott AM; Simes J; Solomon BJ; MacDiarmid JA; Brahmbhatt H; Rosenthal MA
    J Clin Neurosci; 2015 Dec; 22(12):1889-94. PubMed ID: 26279503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions.
    Patel M; Vogelbaum MA; Barnett GH; Jalali R; Ahluwalia MS
    Expert Opin Investig Drugs; 2012 Sep; 21(9):1247-66. PubMed ID: 22731981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intraarterial drug delivery for glioblastoma mutiforme: Will the phoenix rise again?
    Joshi S; Ellis JA; Ornstein E; Bruce JN
    J Neurooncol; 2015 Sep; 124(3):333-43. PubMed ID: 26108656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment.
    Guo G; Narayan RN; Horton L; Patel TR; Habib AA
    Curr Cancer Drug Targets; 2017; 17(3):297-302. PubMed ID: 28004613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Perspectives in Glioblastoma: Nanoparticles-based Approaches.
    Luciano R; Battafarano G; Saracino R; Rossi M; Perrotta A; Manco M; Muraca M; Del Fattore A
    Curr Cancer Drug Targets; 2017; 17(3):203-220. PubMed ID: 27528362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.